C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) A01N 47/40 (2006.01) C07H 21/02 (2006.01) C07H 21/04 (2006.01) C12N 15/11 (2006.01) C12N 15/63 (2006.01) C12P 19/34 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2463521
Antisense compounds, compositions and methods are provided for modulating the expression of insulin-like growth factor binding protein 5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding insulin-like growth factor binding protein 5. Methods of using these compounds for modulation of insulin-like growth factor binding protein 5 expression and for treatment of diseases associated with expression of insulin-like growth factor binding protein 5 are provided.
L'invention concerne des composés antisens, des compositions et des procédés servant à moduler l'expression de la protéine de liaison 5 des facteurs de croissance de type insuline. Lesdites compositions comprennent des composés antisens, en particulier des oligonucléotides antisens, ciblés sur des acides nucléiques codant la protéine de liaison 5 des facteurs de croissance de type insuline. L'invention concerne en outre des procédés d'utilisation desdits composés pour la modulation de l'expression de la protéine de liaison 5 des facteurs de croissance de type insuline et pour le traitement de maladies associées à l'expression de la protéine de liaison 5 des facteurs de croissance de type insuline.
Borden Ladner Gervais Llp
Isis Pharmaceuticals Inc.
LandOfFree
Antisense modulation of insulin-like growth factor binding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of insulin-like growth factor binding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of insulin-like growth factor binding... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1463889